INTRODUCTION
Induction of labour is a method of artificially or prematurely stimulating labour in women. When the risks of continuation of pregnancy either to the mother or to the fetus are more, induction is indicated. Transition from pregnancy to labour is a gradual process, called prelabour marked by increased uterine contractility and cervical ripening. The success of induction depends on the degree of these pre-labour changes. Bishop's score and fetal maturity is to be assessed prior to induction. If Bishop's score is less than 6, it is recommended that a cervical ripening agent be used before labour induction.
Prostaglandins are highly efficacious cervical ripening agents that are useful clinically as an adjuvant to labour induction in patients with unfavourable cervix to shorten induction to delivery interval, improve induction success, and reduce morbidities associated with prolonged labour induction. The use of these agents, however, is associated with potential for uterine contraction and fetal heart tracing abnormalities. Cardiotocography is an electronic method of simultaneously recording fetal heart rate (FHR), fetal movements and uterine contraction to identity the probability of fetal compromise. Cord blood gas analysis monitors the arterial and venous cord blood for levels of oxygen and carbon dioxide while also testing the pH. Essentially, the test tells whether the infant has been subjected to oxygen deprivation at birth.
METHODS
This study was conducted in the Department of Obstetrics and Gynecology of G.S.V.M. Medical College, Kanpur. A total of 80 patients were studied. A written informed consent was taken from those who volunteered to participate. All the cases were randomly divided into two groups each having n=40. In first group 50 µgm misoprostol per vaginally was used for induction of labour and in second group 0.5 mg of dinoprostone gel was used for induction.
Main inclusion criteria were singleton pregnancy with vertex presentation and unfavourable cervical bishop score of 5 or less. There should be no spontaneous uterine contraction (i.e. <4 spontaneous contraction per hour) & non stress test should be reactive. There should be no contraindication to vaginal delivery.
Main exclusion criteria were ruptured membranes & suspected chorioamnionitis, parity more than five, previous caesarean delivery or history of uterine surgery and previous attempted induction of labour for this pregnancy.
Cardiotocography of all the study candidates was performed to rule out fetal distress and presence of uterine contractions. A cervical Bishop Score was assigned on admission to all patients in the study. Participants were then randomly assigned to preinduction cervical ripening with misoprostol 50mcg intravaginally in the posterior fornix initially and repeat dosing 6 hours later or dinoprostone gel 0.5mg administered intracervically initially with repeat dosing 6 hours later. Patients with established contractions pattern of greater than 3 contractions in 10 minutes were not redosed with study agents. After the preinduction interval, a repeat Bishop score was assigned to the patients. Patient not in an adequate labour pattern after the preinduction interval received standard oxytocin infusion, until an adequate contraction pattern was obtained. Electronic fetal heart rate and tocodynamic monitoring was done. Standardized intrapartum management guidelines were followed for all patients. Cardiotocographic tracings were reviewed and any abnormalities were coded using established definitions.
Immediately after delivery a segment of umbilical cord was double clamped and blood was taken from the artery using pre-heparinized syringe and sent to laboratory to determine pH and blood gas values.
RESULTS
Majority of patients in both misoprostol and dinoprostone groups were primigravida (62%). A total of 50 patients were primigravida out of which 28 were in misoprostol group (70%) and 22 were in dinoprostone group (55%). Maximum numbers of patients in both the groups were in the age group 20-25 years. Mean age group in the misoprostol group was 24.575 ± 2.44 and in dinoprostone group was 24.90 ± 2.34.
45% patients in Misoprostol group required only single dose while 60% cases in dinoprostone group required 2 doses. Average number of doses required in misoprostol and dinoprostone group is 1.95 ± 0.7494 and 1.70 ± 0.5639 respectively. Mean induction delivery interval in Misoprostol group is 11.85 ± 4.26 hr. Mean induction delivery interval in dinoprostone group is 12.75 ± 4.22 hr. Incidence of caesarean section was 20% in misoprostol and 17.5% cases in dinoprostone group. Table 1 shows that overall cardiotocographic abnormalities occurred in 45% cases of Misoprostol group and in 17.5% cases of dinoprostone group. In misoprostol group tachysystole occurred in 30%, Hypertonus in 2.5% and hyperstimulation in 12.5% cases while in dinoprostone group 12.5% had tachysystole, 5% had hyperstimulation and none had hypertonus. Table 2 shows that mean time of appearance of cardiotocographic abnormality in misoprostol group is 6.69 ± 3.28hr and in dinoprostone group is 7.86 ± 3hr. Table 4 shows that Baby's APGAR score at 1 and 5 min is an important parameter to assess the well-being of neonate after delivery. Mean APGAR score at 1 min in misoprostol group was 6.3 ± 1.47 and in dinoprostone group was 6.45 ± 1.395. Mean APGAR score at 5 min in misoprostol group was 8.575 ± 0.8439 and in dinoprostone group it was 8.40 ± 0.6718. The perinatal outcome in form of NICU admissions was 20% misoprostol group and 15% in dinoprostone group. 
DISCUSSION
45% percent of women treated with misoprostol demonstrated an abnormal tracing event within the initial 24 hours of induction, compared with 17.5% in the dinoprostone gel. Both hypertonus and tachysystole events were significantly more frequent in women treated with misoprostol compared with either the dinoprostone gel. Logistic regression analysis was applied to assess this difference. Result showed that Regression coefficient is statistically significant (p = 0.0099) which can be interpreted clinically as occurrence of cardiotocographic abnormalities is more in misoprostol group and this difference is statistically significant. The odds ratio is 0.2593 which implies that the probability of cardiotocographic abnormality is 0.2593 times less in dinoprostone group. We can also say that it is 3.8 times more in misoprostol group. In addition we have found that these events occurred earlier after initial misoprostol dosing (6.98 ± 4.14 hr), compared with the dinoprostone gel (9.19 ± 6.29 hr). For analysing this difference independent sample 't' test has been used and value of 't' came out to be 1.37, p=0.1795 which implies that this difference is statistically not significant and may be due to chance as well. Frohn WE et al. (2002) 1 reported that Tachysystole occurred in 20% and 6% of women in misoprostol and PGE 2 respectively. Hyper stimulation occurred in 9% and 6%. They concluded that intravaginal misoprostol is more effective than local PGE 2 application to treat PROM after 34 weeks of gestation but tachysystole occurs more commonly with misoprostol. Gregson S et al. (2005) 2 however reported that the incidence of uterine contraction abnormalities (tachysystole and hyperstimulation) and the incidence of abnormal CTG recordings were similar for both groups. Ramsey P. S. et al. (2005) 3 also reported that cardiotocographic abnormalities are more frequent after misoprostol administration compared with dinoprostone analogue. In their study 55% women treated with misoprostol demonstrated an abnormal tracing event within initial 24 hours of induction, compared to 31.4% with dinoprostone gel. In addition these events occurred earlier after misoprostol dosing (1.6 ± 5.6 hours) compared to dinoprostone gel (7.7 ± 6.6 hours).
FHR <110 bpm (bradycardia) was seen in 5% cases with misoprostol and 2.5% cases with dinoprostone. FHR>160 bpm (tachycardia) was seen in 10% cases with misoprostol and 7.5% cases with dinoprostone and this difference is statistically insignificant (p=0.375) FHR variability was less than 5 in 10 % cases of misoprostol group and 7.5% cases of dinoprostone group and this difference is statistically insignificant (p=0.623). No accelerations were present in 5% cases of both misoprostol and dinoprostone group. Decelerations were present in 22.5% cases of misoprostol and 17.5% cases of dinoprostone group. Logistic regression analysis was applied to assess this difference which showed that occurrence of decelerations in misoprostol and dinoprostone group is statistically not significant (p=0.577). Langenegger EJ et al. (2005) 4 found that there were no significant differences in respect of the number of vaginal deliveries within 24 h (RR 1.12; 95% CI 0.88-1.42) between misoprostol and dinoprostone group. The frequency of suspicious and pathological fetal heart rate patterns did not differ significantly.
Baby's APGAR score at 1 and 5 min is an important parameter to assess the well-being of neonate after delivery. Mean APGAR score at 1 min in misoprostol group was 6.3 ± 1.47 and in dinoprostone group was 6.45 ± 1.395. Independent 't' test was applied to analyse the difference between APGAR score and it was found to be statistically not significant (t = 0.468 and p = 0.6411). Mean APGAR score at 5 min in misoprostol group was 8.575 ± 0.8439 and in dinoprostone group it was 8.40 ± 0.6718. Independent 't' test was applied to assess this difference and it was found to be statistically not significant (t = 1.026 and p = 0.308). 6 also observed that mode of delivery, rate of cesarean sections due to fetal distress and adverse neonatal outcome were not demonstrated to be significantly different between misoprostol and dinoprostone groups (P = 1, P = 0.5, P = 0.4, P = 0.22, P = 0.5).
Mean umbilical arterial pH, PCO 2 , PO 2 and base excess in misoprostol group was 7.21 ± 0.039; 56.07 ± 2.53; 21.3 ± 4.52 and 4.24 ± 0.34 respectively and in dinoprostone group was 7.21 ± 0.034; 55.66 ± 2.39; 19.7 ± 4.185 and 4.24 ± 0.34 respectively. Independent t test was applied and it was found to be statistically not significant (For pH t = 0.425 and p = 0.672; PCO 2 t = 1.647 and p = 0.103; PO 2 t = 0.757 and p = 0.451 and base excess t = 0.099 and p = 0.921). Similar results were reported by Mundle W. R. et al. (1996) . 7 They found that mean (±SD) time to vaginal delivery was 753 ± 588 minutes for misoprostol versus 941 ± 506 minutes for the physician chosen combination (P = 0.018). There was no significant difference in caesarean rate or maternal morbidity. Neonatal outcomes, including cord blood acid base analysis were not significantly different.
CONCLUSIONS
Thus we can conclude from our study that both misoprostol and dinoprostone are effective drugs for induction of labour with no significant difference in induction delivery interval, oxytocin requirement and mode of delivery. Neonatal outcome in terms of cord blood gas analysis, APGAR score at 1 and 5 minutes, NICU admission are apparently similar in both. However cardiotocographic abnormalities are more frequent after misoprostol administration compared with the dinoprostone gel so misoprostol should be cautiously used with continuous fetal heart rate and tocodynamic monitoring.
